Blog
To the ABIM: What real life-long learning should look like
He left a little early to stop by the cath lab to see his patient before her procedure. Cordial “Hello’s” and “Good mornings” and “Any last questions?” were mentioned before she signed her consent. The team was working feverishly to prepare her for her procedure. “Have you met the anesthesiologist yet?” was next, and almost on cue, the anesthesiologist arrived and took over for a bit.
Solving medical mysteries: The Undiagnosed Disease Network
Where to teach?
As I begin another year teaching EKG’s to our new residents, I find I am increasingly asking myself “Where to teach?”
FDA researchers build partnerships to advance innovations
Heather Tate, author of “NARMS investigation of an increase in Salmonella serotype IIIa 18:z4,z23:- isolated from retail meats and humans,” discussing her poster with David G. White, Ph.D., Chief Science Officer and Research Director, FDA Office of Foods and Veterinary Medicine, at the 4th Annual FDA Foods and Veterinary Medicine Science and Research Conference.
By David G. White, Ph.D.
De-risking drug development: Funding science with financial engineering
By Ed Anderson
There’s no way around it. Obtaining approval to market a new drug is lengthy, complex, costly and fraught with uncertainty and risk. Financial engineers at MIT propose a strategy to minimize that risk – one that deserves a close look.
Stem cell medicine gets a “roadmap” and a quality assurance tool
If you’ve lost your way on the Boston subway, you need only consult a map to find the best route to your destination. Now stem cell engineers have a similar map to guide the making of cells and tissues for disease modeling, drug testing and regenerative medicine. It’s a computer algorithm known as CellNet.
Who is most at risk for PTSD after trauma? Lessons from the Boston Marathon bombings
By Daniel Busso
More than 60 percent of teenagers have experienced a traumatic event in their lifetime, but only a minority will develop post-traumatic stress disorder (PTSD). For both researchers and clinicians, this raises an important question: Why are some youth at greater risk for mental health problems after trauma? As our lab reports in two recent studies, conducted after the 2013 Boston Marathon bombings, the answer may lie in our neurobiology.
Clinical trials: Enhancing data quality, encouraging participation and improving transparency
Providing easy access to medical device reports submitted to FDA since the early 1990s
Search for brain tumor biomarkers in urine strikes gold
By Tom Ulrich
A good biomarker is one whose levels go up or down as a patient’s disease worsens or wanes. A great biomarker also gives key insights into disease development. A really great biomarker does both of these things and also serves as a treatment target.